Montreal, Canada
VVector Bio, founded in 2019, is a Canadian company specializing in Contract Development and Manufacturing Organization (CDMO) services for viral vector manufacturing. The company plays a crucial role in advancing cell and gene therapy development by offering expertise in the production of Lentivirus and adeno-associated virus (AAV) using HEK-293 suspension cells. Their technological prowess extends to manufacturing AAV from the baculovirus-insect cell system.
With a focus on the biopharma, biotechnology, and clean energy sectors, VVector Bio supports vaccine and therapeutic projects, delivering process and analytical development for recombinant adenovirus vectors and enveloped virus-like particles. The company's commitment to innovation aims to enhance efficiency and cost-effectiveness, ensuring access to cell and gene therapy for patients in need. Despite lacking recent investment activities, VVector Bio stands out by leaning heavily on its core mission encapsulated in its slogan: "Offering excellent CDMO services for viral vector manufacturing to support cell and gene therapy development."
Virica Biotech